Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson’s disease.

12

Transcript of Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson’s disease.

Page 1: Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson’s disease.
Page 2: Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson’s disease.
Page 3: Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson’s disease.
Page 4: Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson’s disease.
Page 5: Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson’s disease.
Page 6: Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson’s disease.
Page 7: Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson’s disease.
Page 8: Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson’s disease.
Page 9: Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson’s disease.
Page 10: Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson’s disease.
Page 11: Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson’s disease.
Page 12: Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson’s disease.

Dopamine Axon Varicosities in the Prelimbic Division of the Rat Prefrontal Cortex Exhibit Sparse Immunoreactivity for the Dopamine Transporter

Dopamine Axon Varicosities in the Prelimbic Division of the Rat Prefrontal Cortex Exhibit Sparse Immunoreactivity for the Dopamine Transporter

Behavioral effects of the R-(+)- and S-(−)-enantiomers of the dopamine D1-like partial receptor agonist SKF 83959 in monkeys

Behavioral effects of the R-(+)- and S-(−)-enantiomers of the dopamine D1-like partial receptor agonist SKF 83959 in monkeys

Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinaesia

Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinaesia

adrenergic agonist

adrenergic agonist

Self-unawareness of levodopa induced dyskinesias in patients with Parkinson’s disease

Self-unawareness of levodopa induced dyskinesias in patients with Parkinson’s disease

Structural Basis of Dopamine Receptor Activation

Structural Basis of Dopamine Receptor Activation

AANA Journal Course—α2-Adrenergic Receptor Agonist, an ...

AANA Journal Course—α2-Adrenergic Receptor Agonist, an ...

(−)-N-[11C]propyl-norapomorphine: a positron-labeled dopamine agonist for PET imaging of D2 receptors

(−)-N-[11C]propyl-norapomorphine: a positron-labeled dopamine agonist for PET imaging of D2 receptors

On the Existence of a Possible A2A–D2–β-Arrestin2 Complex: A2A Agonist Modulation of D2 Agonist-Induced β-Arrestin2 Recruitment

On the Existence of a Possible A2A–D2–β-Arrestin2 Complex: A2A Agonist Modulation of D2 Agonist-Induced β-Arrestin2 Recruitment

The dopamine D3 receptor partial agonist CJB090 and antagonist PG01037 decrease progressive ratio responding for methamphetamine in rats with extended-access: D3 partial agonist on

The dopamine D3 receptor partial agonist CJB090 and antagonist PG01037 decrease progressive ratio responding for methamphetamine in rats with extended-access: D3 partial agonist on

Investigating quality of life in Bulgarian patients with Parkinson’s disease.

Investigating quality of life in Bulgarian patients with Parkinson’s disease.

Biosignatures for Parkinson’s Disease and Atypical Parkinsonian Disorders Patients

Biosignatures for Parkinson’s Disease and Atypical Parkinsonian Disorders Patients

Spatial reversal learning in chronically sensitized rats and in undrugged sensitized rats with dopamine D2-like receptor agonist quinpirole

Spatial reversal learning in chronically sensitized rats and in undrugged sensitized rats with dopamine D2-like receptor agonist quinpirole

Cariprazine (RGH-188), a Dopamine D3 Receptor-Preferring, D3/ D2 Dopamine Receptor Antagonist–Partial Agonist Antipsychotic Candidate: In Vitro and Neurochemical Profile

Cariprazine (RGH-188), a Dopamine D3 Receptor-Preferring, D3/ D2 Dopamine Receptor Antagonist–Partial Agonist Antipsychotic Candidate: In Vitro and Neurochemical Profile

Sleep problems reported by patients entering opioid agonist treatment

Sleep problems reported by patients entering opioid agonist treatment

Dopamine and Glutamate Induce Distinct Striatal Splice Forms ...

Dopamine and Glutamate Induce Distinct Striatal Splice Forms ...

Quantitative Gait Analysis in Parkinson’s Disease: Comparison With a Healthy Control Group

Quantitative Gait Analysis in Parkinson’s Disease: Comparison With a Healthy Control Group

A Framework for Mesencephalic Dopamine Systems Based on

A Framework for Mesencephalic Dopamine Systems Based on

Parkinson’s disease-related disorders in the impulsive-compulsive spectrum

Parkinson’s disease-related disorders in the impulsive-compulsive spectrum

Determination of enantiomeric purity of the new D-2 dopamine agonist 2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin (N-0437) by reversed-phase high-performance liquid chromatography

Determination of enantiomeric purity of the new D-2 dopamine agonist 2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin (N-0437) by reversed-phase high-performance liquid chromatography